Oligonucleotide CDMO Market to Hit US$6.73 Billion by 2029 with 21.8% CAGR

Browse 270 market data Tables and 56 Figures spread through 254 Pages and in-depth TOC on "Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029
Global Oligonucleotide CDMO Market Poised for Strong Growth

The global Oligonucleotide Contract Development and Manufacturing Organization (CDMO) market [https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-cdmo-market-227700087.html], valued at US$2.33 billion in 2023, is projected to expand at an impressive CAGR of 21.8%, reaching US$2.51 billion in 2024 and US$6.73 billion by 2029. Key drivers of this growth include the increasing outsourcing of drug development and manufacturing to CDMOs and the rising demand for precision and personalized medicine. Additionally, growing investments in oligonucleotide-based therapeutics are further fueling market expansion.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=227700087 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=227700087&utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=oligonucleotidecdmomarket]

Market Segmentation and Growth DriversDominance of Contract Manufacturing Services

The oligonucleotide CDMO market is categorized into contract development, contract manufacturing, and other services. Among these, the contract manufacturing segment is expected to lead the market, driven by the need for large-scale, cGMP-compliant production of oligonucleotide APIs for both clinical and commercial applications. CDMOs with advanced solid-phase synthesis platforms, high-throughput purification technologies, and automated fill-finish systems are instrumental in meeting the demand for ASOs, siRNAs, and mRNA-based therapeutics.

Within contract manufacturing, the commercial segment is anticipated to dominate, supported by the rising number of FDA-approved oligonucleotide-based therapeutics and their expanding applications in chronic diseases and oncology. The demand for large-scale manufacturing for late-stage clinical trials and commercial APIs is driving investment in cGMP production capabilities. The growing adoption of lipid nanoparticles for mRNA-based therapies is further propelling the market.

Therapeutic Applications Leading the Market

The market is segmented by applications into therapeutic, diagnostic, and research applications. In 2023, the therapeutic applications segment held the largest share, driven by increasing oligonucleotide drug approvals targeting genetic disorders, oncology, and rare diseases. Innovations in delivery platforms, such as lipid nanoparticle encapsulation, and stringent regulatory requirements for cGMP manufacturing are solidifying this segment's dominance.

Regional Insights: North America & Asia Pacific

The market is geographically divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. While Asia Pacific registered the highest CAGR in 2023, North America remains the dominant region, driven by its advanced pharmaceutical infrastructure, strong biotech presence, and substantial R&D investments in oligonucleotide therapeutics. The presence of leading CDMOs equipped with automated synthesis and high-throughput purification technologies, along with favorable regulatory frameworks, ensures North America's continued market leadership.

Competitive Landscape: Key Players & Strategic Initiatives

The oligonucleotide CDMO market is highly consolidated, with key players implementing various strategies, including product innovations, partnerships, expansions, and acquisitions, to strengthen their market position.

Leading Companies in the Market:

*
Thermo Fisher Scientific Inc. (US)

*
Lonza (Switzerland)

*
Agilent Technologies, Inc. (US)

*
Kaneka Eurogentec S.A. (Belgium)

*
Ajinomoto Co., Inc. (Japan)

*
Aurigene Pharmaceutical Services Ltd. (India)

*
Bachem (Switzerland)

*
Syngene International Limited (India)

*
PolyPeptide Group (Switzerland)

*
WuXi AppTec (China)

*
EUROAPI (France)

*
Eurofins Scientific (Luxembourg)

*
GenScript (US)

*
Danaher Corporation (US)

Company Highlights:

*
Bachem: Specializes in oligonucleotide and peptide-based therapeutics. The company's expertise in large-scale oligonucleotide API manufacturing and collaborations with major pharma biotech companies position it as a leading CDMO. Notably, Bachem partnered with Eli Lilly in April 2022 for the development and manufacturing of oligonucleotide-based drug substances.

*
Agilent Technologies: Offers a comprehensive portfolio of oligonucleotide CDMO services, including custom synthesis, process optimization, and large-scale manufacturing. Its strong brand presence and geographic reach solidify its market position.

*
Thermo Fisher Scientific: Leverages its advanced solid-phase synthesis, proprietary purification technologies, and high-throughput systems to provide end-to-end oligonucleotide manufacturing solutions. The company's OligoPerfect Primer Designer platform accelerates development timelines, particularly for ASOs and siRNA therapeutics.

Conclusion

The oligonucleotide CDMO market is experiencing rapid expansion, driven by the outsourcing trend, regulatory advancements, and the increasing adoption of oligonucleotide-based therapies. As key players continue to innovate and expand their capabilities, the market is expected to sustain its strong growth trajectory over the coming years.

For more information, Inquire Now! [https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=227700087&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=oligonucleotidecdmomarket]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=oligonucleotide-cdmo-market-to-hit-us673-billion-by-2029-with-218-cagr]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-cdmo-market-227700087.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.